Passage Bio (PASG)
US Market

Passage Bio (PASG) Stock Price & Analysis


PASG Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.58 - $1.92
Previous Close$0.62
Average Volume (3M)206.92K
Market Cap
Enterprise Value-$72.27M
Total Cash (Recent Filing)$132.78M
Total Debt (Recent Filing)$26.52M
Price to Earnings (P/E)-0.3
Feb 29, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.06
Shares Outstanding54,819,638
10 Day Avg. Volume299,900
30 Day Avg. Volume206,920
Standard Deviation0.19
Financial Highlights & Ratios
Price to Book (P/B)0.27
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.65
Price Target Upside862.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2



Ownership Overview

5.87% Mutual Funds
47.05% Other Institutional Investors
47.08% Public Companies and
Individual Investors


What was Passage Bio’s price range in the past 12 months?
Passage Bio lowest stock price was $0.57 and its highest was $1.92 in the past 12 months.
    What is Passage Bio’s market cap?
    Currently, no data Available
    When is Passage Bio’s upcoming earnings report date?
    Passage Bio’s upcoming earnings report date is Feb 29, 2024 which is in 92 days.
      How were Passage Bio’s earnings last quarter?
      Passage Bio released its earnings results on Nov 13, 2023. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.457 by -$0.033.
        Is Passage Bio overvalued?
        According to Wall Street analysts Passage Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Passage Bio pay dividends?
          Passage Bio does not currently pay dividends.
          What is Passage Bio’s EPS estimate?
          Passage Bio’s EPS estimate is -$0.42.
            How many shares outstanding does Passage Bio have?
            Passage Bio has 54,819,637 shares outstanding.
              What happened to Passage Bio’s price movement after its last earnings report?
              Passage Bio reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.457. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Passage Bio?
                Among the largest hedge funds holding Passage Bio’s share is Versant Venture Management, LLC. It holds Passage Bio’s shares valued at 3M.


                  Company Description

                  Passage Bio

                  Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.


                  Top 5 ETFs holding PASG

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Up to five ETFs with an Outperform Smart Score that hold PASG. The ETFs are listed according to market value of PASG within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Ascendis Pharma
                  Voyager Therapeutics
                  Sangamo Biosciences

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis